Schering AG/Chiron Betaseron Label Expansion For Early MS Expected By Q4
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Schering AG expects expanded approval of its multiple sclerosis therapy Betaseron in the fourth quarter to allow earlier use for newly emergent disease
You may also be interested in...
Oncology, CNS Agents May Dominate 2006 NME Approvals
Bristol-Myers Squibb’s multi-targeted kinase inhibitor dasatinib and Genta’s Bcl-2 inhibitor Genasense (oblimersen) could be approved for leukemia indications in the first half of 2006, if granted priority reviews. Both agents were submitted in late December.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product